May 5, 2020 to Members of the United States Senate and House Of

Total Page:16

File Type:pdf, Size:1020Kb

May 5, 2020 to Members of the United States Senate and House Of May 5, 2020 To Members of the United States Senate and House of Representatives: Wisconsin’s primary election on April 7th of this year was an expression of the democratic spirit in a crisis, as thousands lined up to fulfill their civic duty. The right to vote is an essential element of our democracy and Americans should not have to choose between their rights of citizenship and their own health. For epidemiologists and public health experts, Wisconsin’s election took on other meanings, alarming many of us who have devoted ourselves to combating infectious diseases for all of our professional lives. Despite the Wisconsin Governor’s plan to delay the election until June because of the COVID-19 pandemic, the state legislature and the state supreme court refused to allow this postponement. Thus, many of us in public health looked on with horror as thousands of people in Wisconsin were forced to choose between exercising their right to vote and staying home to protect themselves from exposure to the new coronavirus SARS-CoV-2; those choosing the former were imperiling their own lives by voting in person that day. Though there were new cases of COVID-19 among those who voted in person that day and those who worked at the polls in Wisconsin, the impact of the decision to go ahead with the primary on April 7th on the spread of the disease may never be known. However, as Dr. Ben Weston, the Medical Director for the Milwaukee County Office of Emergency Management, has said: "While we continue to monitor cases of Covid-19 linked to election activity, we know that gatherings such as (the election) are detrimental to the efforts to slow the spread of this pandemic." Americans should never again be asked to choose between performing one of the most hallowed obligations and privileges of citizenship—voting for our representatives at the local, state and federal levels—and our health. This November 2020, we have a Presidential election before us. We also have the prospect of a resurgence of the coronavirus, SARS-CoV-2, which to date has killed nearly 70,000 Americans and infected more than one million people in the United States. Both the Director of the Centers for Disease Control and Prevention, Dr. Robert Redfield, the Director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, along with many other scientists, have warned about the possibility of a resurgence of SARS-CoV2 this fall. Furthermore, until an effective vaccine is developed and widely administered in the US, intermittent outbreaks of COVID-19 may reoccur at least until 2022. The potential for reoccurrences of SARS-CoV-2 will require new rounds of social distancing to keep each outbreak in check. In order to ensure the integrity of the electoral process and protect the public health at the same time, it is incumbent on our leaders to prepare for a Presidential election by mail, in which ballots are sent to all registered voters, to allow them to vote from home and ensure their health and safety in the event of a new outbreak of SARS-CoV-2. Several states already conduct most elections by mail, and many states are preparing for by-mail voting in the fall. However, states will need resources to rapidly prepare to ensure that a vote-by-mail option is available to all voters. The costs of this effort—for ballot printing, postage costs, dropboxes for absentee ballots and appropriate security, secure electronic absentee ballot request technology, ballot tracking, improvements to absentee ballot processing, including additional facilities and staffing—are estimated to total $4 billion and will require a Congressional appropriation to support this work. In addition, while we hope most Americans will have the opportunity to vote by mail, maintaining the safety of in- person voting will also be required for November 2020, as well as subsequent elections as long as SARS-CoV-2 circulates in the US. These additional measures, including those that ensure polling facilities that meet public health standards, will entail $271.4 million in federal funds. Members of Congress must ensure funding for the rapid scale-up of by-mail voting nationwide in time for the 2020 Presidential election, and our local and state election officials must do all they can to support American citizens’ right to vote, while protecting them from SARS-CoV-2 infection, from spreading the virus during a pandemic. The right to vote should not have to be sacrificed or compromised to ensure our health and safety. If you act now, we can all vote without fear of acquiring or spreading COVID-19 as we exercise this fundamental democratic right in November 2020. Respectfully yours, Name Title Institution Yale School of Public Health and Yale Law Gregg Gonsalves, PhD Associate Professor School Carl T. Bergstrom, PhD Professor University of Washington Laurie Litman, MS President 350 Sacramento John Beardsley, BA, LMT Retired 350 Seattle Michael O'Loughlin, PhD Professor Adelphi University Scott Pytluk, PhD Core Faculty Adler University Amelia Hausauer, MD Director of Dermatology Aesthetx Jeffrey Bruce Hillenberg, PhD Psychologist Affiliated Psychologists of Michigan Katherine E. Ginsbach, MS, JD Medical- Legal Partnership Attorney Alaska Native Medical Center George Shaw, MD Physician Allegheny Health Network Carly M. Goldstein, PhD Assistant Professor (Research) Alpert Medical School of Brown University Donna M. Staton, MD, Pediatrician and Director of International MPH Community Access to Child Health Program American Academy of Pediatrics Linda Garcia-Shelton, Clinical Psychologist, and Public Health American Board of Professional Psychology PhD, MHSA Practitioner Foundation Kitturah Schomberg- Klaiss, DO Physician American Family Care Phyllis Rifkin-Russell, LMHC, CGP Psychotherapist American Group Psychotherapy Association Linda Garcia- Shelton, PhD, MHSA Clinical Health Psychologist American Psychological Association Joyce R. Gaufin, BS Former President American Public Health Association Thespina Yamanis, MPH, PhD Associate Professor American University Michael Friedman, MPH, PhD Assistant Professor American University of Antigua Marie Coignet, PhD Epidemiologist, Staff Scientist AncestryDNA Adam Hege, PhD, MPA Professor Appalachian State University Gregory N. Shrader, PhD Psychologist Arizona State University Mindy McEntee, PhD Postdoctoral Scholar Arizona State University Arnhold Institute for Global Health, Icahn Duncan Maru, MD, PhD Senior Faculty School of Medicine at Mount Sinai Janet K. Ashworth, PhD Clinical Psychologist Ashworth Psychological Services, PLLC Winnifred Cutler, PhD President and Founder Athena Institute for Women's Wellness Mark S Lowenthal, Psy.D Licensed Psychologist Barnabas Health Hoda J Badr, PhD Associate Professor Baylor College of Medicine Baylor College of Medicine and Texas Marisa Hilliard, PhD Associate Professor of Pediatrics Children's Hospital Susan Cheng, PhD, MPH Department Chair and Associate Professor Benedictine University Georgeen Polyak, PhD Associate Professor Benedictine University Mary Walsh, M.Ed. Teacher Big Lake High School Jennifer Thompson, MD Clinical Program Leader Boehringer Ingelheim Pharmaceuticals Stephen Soldz, PhD Professor Boston Graduate School of Psychoanalysis Boston Health Care for the Homeless Mardge Cohen, MD Physician Program Benjamin P Linas, MD, Boston Medical Center and Boston MPH Associate Professor University Jonathan Shaffer PhD Candidate Boston University Jacob Bor, SD Assistant Professor Boston University Avik Chatterjee, MD, MPH Assistant Professor Boston University School of Medicine Carolina Herrera, MA Doctoral Candidate Boston University School of Public Health Jennifer Weuve, MPH, ScD Associate Professor Boston University School of Public Health Calpurnyia Roberts, Boston’s Mayor’s Office of Workforce PhD Senior Policy Manager Development Morgan Shields, Ph.D. (expected 2020) PhD Candidate Brandeis University Research Investigator and Assistant Brigham and Women’s Hospital, Harvard Elizabeth Janiak, ScD Professor Medical School Rachel Mealy, M.S. Doctoral student Brown University Stephanie Catanese, Physician and Assistant Professor of MD Medicine Brown University Josiah D. Rich, MD, MPH Professor of Medicine and Epidemiology Brown University Anashua Rani Elwy, Brown University, Warren Alpert Medical PhD Associate Professor School Brown University, Warren Alpert Medical Sarah Hsu Medical Student School Andrea Boggio, JSD Professor Bryant University David Bezanson, PhD Clinical Psychologist Neuropsychologist CA Climate Health Now Christopher T. Kondo, PhD Professor Cal State Fullerton California Polytechnic State University, Michael Latner, PhD Professor, Research Scientist Union of Concerned Scientists Adele R. Amodeo, MPH Executive Director California Public Health Association-North Lissa Lim, PhD Psychologist California State University San Marcos Jay Robertson-Howell, Psy.D. Psychologist California State University, San Marcos Juan Alvarez, PhD Psychologist California State University, San Marcos Allie P Laurie Jr, M.A. Psychology Intern California State University, San Marcos Cambridge Health Alliance / Harvard Andrew Choi, PhD Psychology Postdoctoral Fellow Medical School Stacey Benson, PhD Managing Health Scientist Cardno ChemRisk Naseem Dillman-Hasso, BA Lab Manager Carleton College Margaret Falbo, DNP Adjunct faculty Carnegie Mellon University Alan D. Levine, PhD Professor Case Western Reserve University Kevin K. Makino, MD, PhD Post-pediatric child psychiatry fellow Case Western Reserve University
Recommended publications
  • Trump to Shut Off Tiktok, Wechat to New U.S. Users on Sunday
    For news and information consider- If you would like to share news or news organization events, and school Mr. Lee’s Commen- ation, please send to If information with our readers, please news to us includinig your name and [email protected] tary and Dairy send the unique stories, business phone number in case more informa- tion is needed. or contact John Robbins 832-280-5815 Jun Gai 281-498-4310 Publisher: Wea H. Lee President: Catherine Lee Editor: John Robbins, Jun Gai Address: 11122 Bellaire Blvd., Houston, TX 77072 E-mail: [email protected] Southern Daily News is published by Southern News Group Daily Inside C2 Saturday September 19 2020 | www.today-america.com | Southern News Group Trump to shut off TikTok, WeChat to new U.S. users on Sunday WASHINGTON (Reuters) - The Trump administration WeChat developer Tencent Holdings’ called the order will ban WeChat and video-sharing app TikTok from U.S. “We have some great options and maybe we can keep a lot of “unfortunate” but said it “will continue to discuss with app stores starting Sunday night, a move that will block people happy,” Trump told reporters. “We have to have the total the government and other stakeholders in the U.S. ways Americans from downloading the Chinese-owned plat- security from China.” to achieve a long-term solution.” forms over concerns they pose a national security threat. Commerce Secretary Wilbur Ross told Fox Business Network that The Commerce Department order bars Apple Inc’s app The bans, announced on Friday, affect only new “the basic TikTok will stay intact until Nov.
    [Show full text]
  • International Symposium on Novel Ideas in Science and Ethics Of
    I N T E R N A T I O N A L S Y M P O S I U M O N N O V E L I D E A S I N S C I E N C E A N D E T H I C S O F V A C C I N E S A G A I N S T C O V I D - 1 9 P A N D E M I C 30 JULY 2020 DEPARTMENT OF HEALTH RESEARCH MINISTRY OF HEALTH AND FAMILY WELFARE, GOVERNMENT OF INDIA International Symposium on Novel ideas in Science and Ethics of Vaccines against COVID-19 pandemic Date: 30th July 2020 / 4:30 pm – 6:45 pm IST (A fully online, multi-country program) Moderated / Facilitated by Chris Anderson, Curator, TED talks Follow Live at - https://icmrvaccines.impcom.in/ Timing (IST) Session Speakers / Discussants Prof K VijayRaghavan Principal Scientific Advisor to Govt. of India Dr Renu Swarup Secretary, Dept of Biotechnology, Government of India 16.30 – 16:36 Welcome and Introductory Statement Prof Heidi Larson Director of The Vaccine Confidence Project (VCP); Professor, London School of Hygiene and Tropical Medicine, UK Prof Adam Kamradt-Scott Director, Global Health Security Network, Associate Professor, University of Sydney, Australia 16:36 – 16:41 Confronting the pandemic Dr Anthony S Fauci Director, National Institute of Allergy and Infectious Diseases, USA 16:42 – 16:43 A short Video Timely & Safe – Towards a Covid-19 Prof Peter Piot vaccine (Leadership remarks)- Role of Director, London School of Hygiene and Tropical Medicine, UK vaccines in ending epidemics Prof Stanley Plotkin 16:45 – 17:06 Introduced by: Mr JVR Prasada Rao Author of Plotkin’s Vaccines, Emeritus Professor, University of Pennsylvania, USA National Task Force COVID-19 member and Former Secretary for Health, Govt.
    [Show full text]
  • Emerging Leaders in Biosecurity Initiative
    Emerging Leaders in Biosecurity Initiative Class of 2017 A competitive fellowship program created to identify, develop, and provide networking opportunities Yearbook for the next generation of leaders in biosecurity. Emerging Leaders in Biosecurity Initiative Contents Letter: 3 Thomas V. Inglesby, Director; Anita Cicero, Deputy Director, Johns Hopkins Center for Health Security Executive Steering Committee 5 Class of 2017 Fellows 9-35 ELBI 2017 Year in Review 36-37 ELBI Program Staff 41 ELBI Alumni 42 Cover and Inside Cover Photo Overlay: Swine Flu Strain Virus Particles. Col- orized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID Emerging Leaders in Biosecurity Initiative The ELBI Fellowship program is made possible through financial support from the Open Philanthropy Project, under management by the Johns Hopkins Center for Health Security, and with the leadership of the ELBI Executive Steering Committee. For more information, please visit the ELBI website: http://www.centerforhealthsecurity.org/our-work/emergingbioleaders Center for Health Security “Modern conditions make the scenario of a global pandemic more likely. Humans are encroaching on animal environments, raising chances for pathogens to adapt from animals to people. An increasing share of the planet lives in megacities, heightening the likelihood of person-to-person transmission of pathogens. The movement of people and microbes around the globe is more efficient than ever. The recent outbreaks of SARS, MERS, and Ebola are only small glimpses of how quickly a deadly virus can spread.” Tom Inglesby and Benjamin Haas Foreign Affairs November 21, 2017 Middle East Respiratory Syndrome Coronavirus particle envelope proteins immunolabeled with Rabbit HCoV-EMC/2012 primary antibody and Goat an- 1 ti-Rabbit 10 nm gold particles.
    [Show full text]
  • San Bernardino County Waiting, for Now, to Expand Stage 2 Coronavirus Reopening – Redlands Daily Facts
    San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening – Redlands Daily Facts LOCAL NEWS • News San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening By SANDRA EMERSON | [email protected] | PUBLISHED: May 19, 2020 at 4:58 p.m. | UPDATED: May 19, 2020 at 10:37 p.m. While San Bernardino County supervisors are eager for restaurants and churches to resume operations after weeks of novel coronavirus-related closures and restrictions, they’re waiting to see how the county’s data pairs with new state guidelines on reopening various sectors. After a lively debate Tuesday, May 19, about the risks associated with reopening ahead of the state, the supervisors agreed to hear more from county staff before expanding the second of the state’s four-phase plan to reopen businesses. Supervisors agreed to meet at 4 p.m. Thursday, May 21, to further discuss the matter. “Our small businesses have sat and waited,” Supervisor Robert Lovingood said. “They’ve waited patiently as long as they can. They cannot suffer this economic suppression any longer.” Lovingood and Supervisor Dawn Rowe supported moving forward with the county’s recovery plan, which assesses the risk of the virus’ spread at businesses and offers guidelines for reopening safely. However, the item was not on the agenda, so the board agreed to schedule a special meeting. https://www.redlandsdailyfacts.com/2020/05/19/san-bernardino-county-waiting-for-now-to-expand-stage-2-coronavirus-reopening/[5/20/2020 8:18:00 AM] San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening – Redlands Daily Facts TOP ARTICLES 1/5 S A By .st0{fill:#FFFFFF;}.st1{fill:#0099FF;} M READ MORE Thousands evacuated as river dams break in central “This is a serious thing we have to do in the right way,” Chairman Curt Hagman said.
    [Show full text]
  • Covid-19 Vaccines Are Coming
    COVID-19 VACCINES ARE COMING. ARE WE READY? Etienne Grass – November 2020 On November 9, companies BioNTech and Pfizer 240 COVID vaccines are currently being developed announced the eagerly awaited preliminary results globally, according to the regular census carried out of their phase 3 clinical trial for a COVID vaccine by the World Health Organization. Of these, the project. While it is unusual for this type of result to WHO asserts 45 are in clinical trials2, although only be published before the trial is finalized, the rolling 35 according to the New York Times3. review procedure sanctioned by regulatory bodies to speed up the assessment of new drugs has The WHO says that 10 products are already tested enabled this transparency.1 in phase 3 , a figure that rises to 11 according to the New York Times, which includes the recent progress If the results have come as a positive surprise, it is of an Indian product in its assessment 4. mainly due to their high level of efficacy. The Food and Drug Administration (FDA) had indicated that it Within these phase 3 trials, four products are being would be ready to authorize a vaccine with more tested in China5 and one in Russia6. We do not have than 50% effectiveness. The first figures available the same level of information on them as on are much higher, at 90%. vaccines developed in the United States and Europe. For several weeks now, the head of the "Operation Technological platforms of current projects Warp Speed" program, Moncef Slaoui, who has been piloting American federal activities in support of Five products have in common that they are vaccine production since May, had been telling the integrated into the American (Operation Warp New York Times to be "confident that there will Speed-OWS), British and European partnerships7.
    [Show full text]
  • Herd Immunity Is an Important—And Often Misunderstood—Public Health Phenomenon
    CORE CONCEPTS Herd immunity is an important—and often misunderstood—public health phenomenon CORE CONCEPTS Amy McDermott, Science Writer In December, Anthony Fauci predicted that 70 to 85% Since the earliest months of the COVID-19 pan- of the United States population may need to be demic, “herd immunity” has become shorthand for vaccinated to achieve “herd immunity” against SARS- the day when enough people are immune to the virus CoV-2 (1). Yet he was very careful to qualify his com- that social distancing can end and healthcare systems ments. “We need to have some humility here,” he said are no longer overwhelmed. People have been clam- ’ in a New York Times interview, “We really don’t know oring to know when we ll get there. But even as Fauci — what the real number is.” (2) Fauci, director of the and other officials continue to try to calculate and communicate—when it might happen, they have to National Institute of Allergy and Infectious Diseases, contend with both public misunderstanding of the admitted that the number could be as high as 90%. term and scientific disagreement over what it means. But even a year into the pandemic, there were too The public health concept of herd immunity has a many uncertainties to offer a definite threshold. And more nuanced definition than its popular usage, which with vaccine hesitancy widespread, he worried that is one reason why predicting when we’ll achieve it re- setting the bar at such a high number would cause mains difficult. In theory, estimating the threshold to the public to despair of ever reaching it.
    [Show full text]
  • Affidavit from Michael Osterholm
    27-CR-20-12951 Filed in District Court State of Minnesota 1/19/2021 3:22 PM STATE OF MINNESOTA DISTRICT COURT COUNTY OF HENNEPIN FOURTH JUDICIAL DISTRICT State of Minnesota, AFFIDAVIT OF MICHAEL T. OSTERHOLM, Ph.D., MPH Plaintiff, V. Derek Michael Chauvin, Court File No.2 27-CR-20-12646 J. Alexander Kueng, Court File No.2 27-CR—20-12953 Thomas Kiernan Lane, Court File No.2 27-CR-20-12951 Tou Thao, Court File No.: 27-CR-20-12949 Defendants. TO: The Honorable Peter Cahill, Judge of District Court, and counsel for Defendants; Eric J. Nelson, Halberg Criminal Defense, 7900 Xerxes Avenue South, Suite 1700, Bloomington, MN 55431; Robert Paule, 920 Second Avenue South, Suite 975, Minneapolis, MN 55402; Earl Gray, 1st Bank Building, 332 Minnesota Street, Suite W1610, St. Paul, MN 55101; Thomas Plunkett, U.S. Bank Center, 101 East Fifth Street, Suite 1500, St. Paul, MN 55101. MICHAEL T. OSTERHOLM, being duly sworn under oath, states as follows: Background and Qualifications 1. My name is Michael Osterholm, and I am an epidemiologist and the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. 2. I am currently a Regents Professor, McKnight Presidential Endowed Chair in Public Health, Distinguished Teaching Professor in the Division of Environmental Health Sciences in the School of Public Health, a professor in the Technological Leadership Institute, and an adjunct professor in the Medical School, all at the University of Minnesota. 27-CR-20-12951 Filed in District Court State of Minnesota 1/19/2021 3:22 PM On November 9, 2020, President-elect Joseph Biden named me to be one of the sixteen members of his Coronavirus Advisory Board.
    [Show full text]
  • Inland Communities of Color Receiving Vaccinations at Slower Rate, Data Shows – Press Enterprise ___
    2/4/2021 Inland communities of color receiving vaccinations at slower rate, data shows – Press Enterprise ___ NEWS •• News Inland communities of color receiving vaccinations at slower rate, data shows Victorville resident Marvin Abella, 32, receives his second vaccination shot of the Pfizer-BioNTech COVID-19 Vaccine by licensed vocational nurse Mayra Aceves at Arroyo Valley High School in San Bernardino on Thursday, Jan. 28, 2021. 500 second doses were scheduled to be given out Thursday with another 500 scheduled for Friday. (Photo by Will Lester, Inland Valley Daily Bulletin/SCNG) By DEEPA BHARATH || [email protected] || OrangeOrange CountyCounty Register PUBLISHED: February 3, 2021 at 6:42 p.m. || UPDATED:UPDATED: February 3, 2021 at 6:42 p.m. https://www.pe.com/2021/02/03/inland-communities-of-color-receiving-vaccinations-at-slower-rate-data-shows/?utm_medium=social&utm_c… 1/8 2/4/2021 Inland communities of color receiving vaccinations at slower rate, data shows – Press Enterprise Communities of color are behind when it comes to being vaccinated for the coronavirus, a disparity Inland Empire officials say they are working to address. In Riverside County, where 50% of the population is Latino, for example, only 17.9% of those who have been vaccinated are Latino while 44.9% are White, county officials said Wednesday, Feb. 3. Meanwhile, 4.1% of the total number of vaccinations administered have been given to African Americans and 10.7% toto AsianAsian Americans,Americans, whichwhich eacheach representrepresent aboutabout 6.5%6.5% ofof thethe countyʼscountyʼs population. Native American and Pacific Islander residents, who represent 0.8% and 0.3% of the population, respectively, account for 0.6% and 0.7% of thosethose vaccinated.vaccinated.
    [Show full text]
  • Framework on Accumulating Evidence Across Outbreaks
    Framework on accumulating evidence across outbreaks NATALIE DEAN DEPARTMENT OF BIOSTATISTICS UNIVERSITY OF FLORIDA WHO R&D BLUEPRINT CONSULTATION ON CLINICAL TRIAL DESIGNS NOVEMBER 29, 2018, GENEVA Kennedy et al. (2016) DOI: 10.1177/1740774515621037 2 Figure: Weekly incidence of Ebola in Guinea 2014–15, and key dates in the ring vaccination trial 3 doi:10.1126/science.aav3996 4 National Academies of Sciences, Engineering, and Medicine (2017) https://doi.org/10.17226/24739 5 http://www.who.int/emergencies/mers-cov/epi-18-september-2018.png 6 Motivation Outbreaks are of unpredictable size and duration All outbreaks represent an opportunity to advance research and development efforts There is considerable risk that trials will be underpowered and results from trials terminated due to low accrual will be inconclusive Prejudgment of promising but inconclusive results can: . Impact decision-making of caregivers and policy makers . Jeopardize the conduct of future confirmatory trials 7 Recommended approach We advocate for the use of a “master protocol” to preserve data confidentiality and trial integrity until the scientific aims have been reliably addressed Master protocol = conventional clinical trial designed to extend across multiple sites and outbreaks Trial results are released only following the advice of an independent data monitoring committee (e.g. stop for efficacy, futility, reached target # of endpoints) and not due to lack of recruitment 8 Practical considerations Multi-site trial in high-risk areas with opportunity to add sites
    [Show full text]
  • Framework for Equitable Allocation of COVID-19 Vaccine (2020)
    THE NATIONAL ACADEMIES PRESS This PDF is available at http://nap.edu/25917 SHARE Framework for Equitable Allocation of COVID-19 Vaccine (2020) DETAILS 260 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-68224-4 | DOI 10.17226/25917 CONTRIBUTORS GET THIS BOOK Helene Gayle, William Foege, Lisa Brown, and Benjamin Kahn, Editors; Committee on Equitable Allocation of Vaccine for the Novel Coronavirus; Board on Health Sciences Policy; Board on Population Health and Public Health Practice; Health FIND RELATED TITLES and Medicine Division; National Academies of Sciences, Engineering, and Medicine; National Academy of Medicine SUGGESTED CITATION National Academies of Sciences, Engineering, and Medicine 2020. Framework for Equitable Allocation of COVID-19 Vaccine. Washington, DC: The National Academies Press. https://doi.org/10.17226/25917. Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine Framework for Equitable Allocation of COVID-19 Vaccine Helene Gayle, William Foege, Lisa Brown, and Benjamin Kahn, Editors Committee on Equitable Allocation of Vaccine for the Novel Coronavirus Board on Health Sciences Policy Board on Population Health and Public Health Practice Health and Medicine Division PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright National Academy of Sciences.
    [Show full text]
  • Literature Overview October 25, 2020. Many Thanks to Peter Reiss!
    Literature Overview October 25, 2020. Many thanks to Peter Reiss! Lipsitch M, Dean N, Understanding COVID-19 efficacy. Science, October 21, 2020. https://science.sciencemag.org/content/early/2020/10/21/science.abe5938 Commentary about. COVID-19 vaccine efficacy by Marc Lipsitch and Natalie Dean Important questions that will likely remain after first vaccine trials are published and should be addressed: - First, trials are typically not powered to establish subgroup-specific efficacy, yet the performance of the vaccine in high-risk groups affects the success of a direct-protection strategy. - Second, can vaccines prevent infection or reduce contagiousness? This matters for achieving indirect protection. Treatment Toculizimab Commentary on tocilizumab studies: https://www.jwatch.org/fw117147/2020/10/20/tocilizumab-covid-19-three-studies-yield- mixed-findings?query=pfwRS&jwd=000020075418&jspc=ID Salvarani C et al, Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia - A Randomized Clinical Trial. JAMA, October 21, 2020. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186 b Design - This is a prospective, open label RCT to evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia in Italy. Eligibility criteria - included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao2/Fio2) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C- reactive protein. Interventions - Patients in the experimental arm received 2 iv doses of tocilizumab. Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy.
    [Show full text]
  • Hazm Mebaireek Hospital to Treat Covid-19 Cases
    BUSINESS | Page 1 QATAR | Page 20 Ashghal implements preventive Qatar Airways Cargo to measures resume belly-hold cargo to combat operations to China virus spread published in QATAR since 1978 TUESDAY Vol. XXXXI No. 11504 March 31, 2020 Sha’ban 7, 1441 AH GULF TIMES www. gulf-times.com 2 Riyals Hazm Mebaireek Hospital to treat Covid-19 cases QNA Kaabi said that this decision is part of Doha the pre-emptive plan that the health- care sector is implementing to ensure that any possible increase in the number amad Medical Corporation of Covid-19 patients is managed. (HMC) has announced the des- He pointed out that Hazm Mebai- Hignation of Hazm Mebaireek reek General Hospital was specifi cally General Hospital as a facility for treat- chosen to treat Covid-19 patients be- ing coronavirus patients, with the aim cause the hospital will provide a mod- of providing high-quality care for such ern and advanced environment for the patients in an integrated facility. treatment of patients, both men and HE the Minister of Public Health Dr women of all nationalities. Hanan Mohamed al-Kuwari said that the Hazm Mebaireek General Hospital rapid transformation of Hazm Mebaireek has 147 beds, including 42 intensive General Hospital into a facility for treating care beds and 105 inpatient beds. coronavirus patients is an example of the The hospital’s capacity can be in- proactive approach in the healthcare sec- creased to 471 beds (221 beds for inten- tor in the face of this epidemic. sive care and 250 beds for inpatients). She added that the ministry started If needed in the future, it can also pro- to move quickly from the beginning vide a Covid-19 emergency depart- and worked to set standards through ment with a capacity of 150 beds.
    [Show full text]